Low dose naltrexone (or LDN) is receiving increasing attention as of late. Here’s what you ought to know.
- It has demonstrated promise in reducing symptoms in conditions such as fibromyalgia, Crohn’s disease, MS and several autoimmune diseases.
- It is still in the experimental stages of use.
- It is inexpensive and well tolerated.
- Currently is often obtained through a compounding pharmacy.
- LDN refers to dosages that are typically 1/10 the dose of that used for opioid addiction.
- Although the dosage may vary, the common dosage per day is 4.5 mg. (1)
- It seems to work by enhancing endogenous opioid production.
- Two recent studies demonstrated that LDN was superior to placebo in treatment of fibromyalgia. (2, 3)
1. Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Younger J1, Parkitny L, McLain D.
2. Arthritis Rheum. 2013 Feb;65(2):529-38. doi: 10.1002/art.37734.
Low-dose naltrexone for the treatment of fibromyalgia. Younger J1, Noor N, McCue R, Mackey S.
3. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. doi: 10.1111/j.1526-4637.2009.00613.x. [PMC free article] [PubMed] [Cross Ref]